Regulatory landscape for CAR-T therapy development in the Brazilian context

Area of Science:

• Immunotherapy
• Hematologic Malignancies
• Regulatory Science

Background:

• Chimeric antigen receptor T-cell (CAR-T) therapy offers significant advancements in treating blood cancers.
• Global implementation of CAR-T therapy is hindered by regulatory, logistical, and manufacturing hurdles.
• Understanding international regulatory differences is key to equitable access, particularly for academic research programs.

Purpose of the Study:

• To review and compare the regulatory pathways, manufacturing requirements, and quality standards for CAR-T therapies in Brazil, the US, and the EU.
• To assess Good Manufacturing Practice (GMP) expectations, analytical validation, biosafety, and infrastructure needs.
• To explore expanded-access mechanisms and real-world clinical experiences.

Main Methods:

• Focused literature search of peer-reviewed articles, institutional guidelines, and regulatory documents (2016-2025).
• Comparative analysis of regulatory frameworks across Brazil, the United States, and the European Union.
• Assessment of key elements including GMP, analytical validation, biosafety, and infrastructure.

Main Results:

• All reviewed jurisdictions prioritize product quality, long-term safety, and traceability in CAR-T therapy regulation.
• Brazil presents unique challenges with multi-agency coordination and infrastructural limitations potentially delaying national CAR-T deployment.
• Global trends highlight the need for enhanced GMP facilities, robust analytical validation, and harmonized regulations for academic and point-of-care manufacturing.

Conclusions:

• Harmonizing regulatory processes and strengthening manufacturing standards are essential for broadening global access to CAR-T therapies.
• Addressing specific national challenges, like those in Brazil, is vital for timely implementation.
• Continued innovation in CAR-T therapy relies on robust regulatory frameworks that support academic and point-of-care manufacturing initiatives.